['ATP-binding cassette transporter A1 (ABCA1) is a key mediator of cholesterol efflux to apoA-I in cholesterol loaded macrophages, a first step of reverse cholesterol transport (RCT) in vivo. Macrophage specific abca1 inactivation or overexpression, respectively, accelerated or suppressed the development of atherosclerosis in mouse models. However, it is yet to be established that the ABCA1 effect is related to specific changes in RCT from the macrophages in vivo.', 'one marrow-derived macrophages from abca1-/- or abca1+/- mice were labeled with 3H-cholesterol-AcLDL or 3H-cholesterol-LDL and injected into abca1+/+ abca1+/- or abca1-/- mice. When injected into abca1+/+ mice, return of 3H-cholesterol from labeled abca1-/- macrophages to serum, liver, bile, and feces was reduced by 50% (P=0.01) compared with control. When labeled wild-type macrophages were injected into abca1-/- mice, as compared with wild-type mice, the return of 3H-cholesterol to serum, liver, bile, and feces was also reduced.'] Is in vivo reverse cholesterol transport from macrophages lacking ABCA1 expression impaired?